Before Benefit News Today

Second Quarter 2022 Results:-- Net revenues of $73.9 million, net loss available to common shareholders of $(15.3) million and diluted GAAP loss per share of $(0.94) –-- Lead Rare Disease asset, Purified Cortrophin® Gel (Repository Corticotrophin Injection USP) 80 U/ml (Cortrophin) net sales of $10.2 million ---- Ad...

08.08.2022 - ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three and six months ended June 30, 2022. “Second quarter net revenues of $73.9 million represent a new quarterly record ...